Nisa Investment Advisors LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 89,882 shares of the pharmaceutical company’s stock after purchasing an additional 11,489 shares during the period. Nisa Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $13,470,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after purchasing an additional 132 shares in the last quarter. Smithfield Trust Co. purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $135,000. FNY Managed Accounts LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $162,000. Fuller & Thaler Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $198,000. Finally, Intact Investment Management Inc. purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $213,000. 93.09% of the stock is currently owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $157.93 on Friday. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $39,940.00, a PE ratio of 202.47, a PEG ratio of 1.87 and a beta of 1.58. Vertex Pharmaceuticals Incorporated has a 1 year low of $79.78 and a 1 year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s revenue was up 39.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.16 EPS. sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on VRTX. JPMorgan Chase & Co. reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, January 9th. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $176.00 price objective on the stock in a report on Monday, January 8th. Bank of America raised Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Friday, January 5th. Oppenheimer upped their target price on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, January 4th. Finally, Deutsche Bank initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They issued a “buy” rating and a $175.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $175.89.
In other news, CEO Jeffrey M. Leiden sold 125,000 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the transaction, the chief executive officer now directly owns 237,407 shares in the company, valued at approximately $33,557,479.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Ian F. Smith sold 2,125 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $155.61, for a total value of $330,671.25. Following the transaction, the chief operating officer now owns 118,013 shares in the company, valued at $18,364,002.93. The disclosure for this sale can be found here. Insiders have sold a total of 358,464 shares of company stock worth $51,830,442 over the last quarter. Corporate insiders own 1.80% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.